Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: A guide to its use in HIV-1 infection

Clinical Drug Investigation

Volumn 32, Issue 10, 2012, Pages 715-722

  Lyseng Williamson, Katherine A ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Clinical Q and A; Emtricitabinerilpivirinetenofovir disoproxil fumarate; HIV infections; Rilpivirine

Indexed keywords

EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; VIRUS RNA;

ABNORMAL DREAMING; ABNORMAL LABORATORY RESULT; AMYLASE BLOOD LEVEL; ARTICLE; CREATININE CLEARANCE; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DRUG COATING; DRUG EFFICACY; DRUG INDICATION; DRUG TOLERABILITY; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; INSOMNIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DISEASE; MIXED INFECTION; NAUSEA; NIGHTMARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; RASH; RISK ASSESSMENT; SIDE EFFECT; SOMNOLENCE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADENINE; ANTI-HIV AGENTS; DEOXYCYTIDINE; DRUG COMBINATIONS; HIV INFECTIONS; HIV-1; HUMANS; NITRILES; ORGANOPHOSPHONATES; PATIENT COMPLIANCE; PYRIMIDINES; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 84865465384     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11209870-000000000-00000     Document Type: Article

References (21)

1. Camacho R, Teofilo E. Antiretroviral therapy in treatmentnaive patients with HIV infection. Curr Opin HIV AIDS 2011; 6 Suppl. 1: S3-11
2. Maltez F, Dorona M, Branco T, et al. Recent advances in antiretroviral treatment and prevention in HIV-infected patients. Curr Opin HIV AIDS 2011; 6 Suppl. 1: S21-30
3. Mathias A, Menning M, Wei X, et al. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF [abstract no. LBPE17]. 18th International AIDS Conference; 2010 Jul 18-23; Vienna
4. Eviplera": summary of product characteristics. London: European Medicines Agency, 2011 Dec 12
5. Complera": US prescribing information. Foster (CA): Gilead Sciences, Inc., 2012 Jun
6. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010 Jan; 44 (1): 157-65
7. Ghosn J, ChaixML, DelaugerreC. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009; 11 (3): 165-73
8. Sanford S. Rilpivirine. Drugs 2012; 72 (4): 525-41
9. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003 Oct; 2 (10): 812-22 (Pubitemid 37361813)
10. Picchio G, Rimsky L, Van Eygen V, et al. Prevalence of rilpivirine resistance-associated mutations (RAMs) in U.S. samples received for routine resistance testing [abstract no. TUPE047]. AIDS 2012: XIX International AIDS conference; 2012 Jul 22-27; Washington, DC
11. Fulco PP, McNicholl IR. Etravirine and rilpivirine: non-nucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents. Pharmacotherapy 2009 Mar; 29 (3): 281-94
12. Azijn H, Tirry I, Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010 Feb; 54 (2): 718-27
13. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011 Jul 16; 378 (9787): 238-46
14. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011 Jul 16; 378 (9787): 229-37
15. Cohen CJ, Molina J-M, Cahn P. Efficacy and safety of rilpirivine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr 2012; 60 (1): 33-42
16. Cohen C, Molina J-M, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the doubleblind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1infected adults [abstract no. TULBPE032]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17-20; Rome
17. Behrens G, Rijnders B, Nelson M, et al. Efficacy and safety outcomes for rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naïve, HIV-1-positive adults with baseline viral load = 100,000 copies/ mL-pooled 48-week ECHO and THRIVE analysis [abstract no. TUPE023]. AIDS 2012: XIX International AIDS conference; 2012 Jul 22-27; Washington, DC
18. Nelson M, Behrens G, Cohen C, et al. Sustained efficacy with low and similar rates of virologic failures in second year observed with rilpivirine (RPV) versus efavirenz (EFV) plus emtricitabine/tenofovir DF (FTC/TDF) in treatment-naive, HIV-1 infected adults: pooled 96-week ECHO and THRIVE analysis [poster no. LBPE7.3/7]. 13th European AIDS Conference (EACS); 2011 Oct 12-15; Belgrade
19. White K, Van Eygen V, Vingerhoets J, et al. Week 96 resistance analysis of the pooled ECHO and THRIVE Truvada subset in treatment-naïve HIV-infected adults with ≤100,000 c.mL baseline viral load [poster no. P187]. 18th Annual Conference of the British HIV Association; 2012 Apr 18-20; Birmingham, UK
20. Palella F, Tebas P, Gazzard B, et al. SPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/ TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves seru [abstract no. TUAB0104]. AIDS 2012: XIX International AIDS conference; 2012 Jul 22-27; Washington, DC
21. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012 Jan 1; 59 (1): 39-46